In this article
The first wave of generic versions of Novo Nordisk’s
GLP-1 weight-loss drugs launched in India over the weekend, with at least five domestic drugmakers undercutting the original price by up to 80%. It comes as the Danish drugmaker’s patent expired on Friday, with the company fighting to maintain its lead in the lucrative market.
India is a critical market, with around 100 million people living with diabetes and nearly a quarter classified as obese. The country is also known as “the world’s pharmacy” with its well-developed generic drugs industry supplying around 20% of global off‑patent medicines.
Sun Pharmaceutical
